Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Rounds Up $30 Million

NEW YORK, Jan. 27-Perlegen Sciences said today that it had closed a private placement of Series C Preferred Stock worth $30 million.


The round was led by Maverick Capital and included both new and repeat investors, among them Eli Lilly, Vulcan Ventures, Unilever Technology Ventures and SB Life Science Ventures.


Perlegen is an Affymetrix spinoff. It is based in Mountain View, Calif.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.